Carboplatin in previously treated multiple myeloma: A cancer and leukemia group B phase II trial

G. A. Omura, R. T. Perri, B. Peterson, C. A. Schiffer

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Carboplatin 400 mg/m2 per month was evaluated as a single agent in 15 patients with multiple myeloma who had had one prior chemotherapy regimen. All but three were judged to have had some degree of refractoriness to prior therapy. Hematologic toxicity was frequent and sometimes severe. There were no responses. Further evaluation of standard-dose single-agent carboplatin in refractory myeloma does not appear warranted.

Original languageEnglish (US)
Pages (from-to)196-198
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number3
DOIs
StatePublished - 1994

Fingerprint Dive into the research topics of 'Carboplatin in previously treated multiple myeloma: A cancer and leukemia group B phase II trial'. Together they form a unique fingerprint.

Cite this